Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...

Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...

A kidney drug taken by millions of Americans has been pulled from the shelves after it was found to be contaminated with a cancer-causing ingredient. In total, 331,590 bottles of cinacalcet ...